Kalaris Therapeutics, Inc. (NASDAQ:KLRS) announced expanded data from its Phase 1a single ascending dose trial evaluating TH103 for the treatment of neovascular age-related macular degeneration.
Following the announcement, the stock jumped nearly 18%.
The clinical-stage biopharmaceutical company stated that the updated data build on previous findings by showing vision improvements and enhanced retinal anatomy.
Expanded Trial Results Highlight Extended Durability
The expanded study analyzed 17 treatment-naive individuals and three treatment-experienced individuals, tracking all 20 participants through a six-month follow-up window.
